Get the Stockscreener App
2.54
3.79%
-0.10
After Hours:
2.51
-0.03
-1.18%
Mural Oncology Plc stock is traded at $2.54, with a volume of 365.79K.
It is down -3.79% in the last 24 hours and up +124.78% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.64
Open:
$2.61
24h Volume:
365.79K
Relative Volume:
0.08
Market Cap:
$45.07M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.68%
1M Performance:
+124.78%
6M Performance:
-23.95%
1Y Performance:
-33.68%
1-Day Range:
$2.52
$2.62
1-Week Range:
$2.52
$2.68
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.54 | 45.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Geode Capital Management LLC Sells 9,027 Shares of Mural Oncology plc (NASDAQ:MURA) - Defense World
Goldman Sachs adjusts positions in Mural Oncology shares By Investing.com - Investing.com Nigeria
BlackRock discloses stake in Mural Oncology By Investing.com - Investing.com South Africa
BlackRock discloses stake in Mural Oncology - Investing.com Australia
Form 8.3Mural Oncology plc - Business Wire
Goldman Sachs adjusts positions in Mural Oncology shares - Investing.com Australia
Goldman Sachs discloses stake in Mural Oncology By Investing.com - Investing.com India
Goldman Sachs discloses stake in Mural Oncology - Investing.com
Renaissance Technologies LLC Boosts Stock Holdings in Mural Oncology plc (NASDAQ:MURA) - Defense World
Ovarian Cancer Market: Epidemiology, Therapies, Companies, - openPR.com
BlackRock discloses stake in Mural Oncology plc - Investing.com
BlackRock discloses stake in Mural Oncology plc By Investing.com - Investing.com India
Goldman Sachs adjusts stake in Mural Oncology - Investing.com
Mural Oncology plc Opening Position Disclosure Under Irish Takeover Rules - Nasdaq
FORM 8.1(a) & (b)Mural Oncology plc - The Manila Times
Mural Oncology Takeover Speculation Heats Up as CEO Stakes Revealed: 900K+ Total Shares - Stock Titan
Tang Capital reports stake in Mural Oncology - Investing.com
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
LMR Partners reports 2.997% stake in Mural Oncology By Investing.com - Investing.com South Africa
BlackRock discloses stake in Mural Oncology amid takeover rules By Investing.com - Investing.com South Africa
Tang Capital reports 1.2% stake in Mural Oncology By Investing.com - Investing.com South Africa
Tang Capital reports 1.2% stake in Mural Oncology - Investing.com Australia
BlackRock discloses stake in Mural Oncology amid takeover rules - Investing.com Australia
LMR Partners reports 2.997% stake in Mural Oncology - Investing.com Australia
Tang Capital discloses stake in Mural Oncology By Investing.com - Investing.com India
Tang Capital discloses stake in Mural Oncology - Investing.com
Solas Capital discloses dealings in Mural Oncology shares By Investing.com - Investing.com India
Solas Capital discloses dealings in Mural Oncology shares - Investing.com
BlackRock reports stake in Mural Oncology By Investing.com - Investing.com India
BlackRock reports stake in Mural Oncology - Investing.com Australia
Quarterly Metrics: Quick and Current Ratios for Mural Oncology plc (MURA) - DWinneX
Geode Capital reports 1.02% stake in Mural Oncology By Investing.com - Investing.com South Africa
Largest borrow rate increases among liquid names - TipRanks
Geode Capital reports 1.02% stake in Mural Oncology - Investing.com
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):